Written by Private MD Labs Medical Writing Team • Last Updated: September 8, 2025
Congenital hypothyroidism is a condition where the thyroid gland does not produce sufficient thyroid hormones from birth. This condition affects approximately 1 in 3,000-4,000 newborns and can lead to severe physical and intellectual disabilities if not detected and treated early. Early diagnosis through blood testing is crucial for normal development.
This test measures the level of free thyroxine (FT4) in the blood, which is the active form of the primary thyroid hormone. Infants with congenital hypothyroidism typically have significantly low FT4 levels. This test is essential for confirming the diagnosis and determining the severity of thyroid hormone deficiency, allowing healthcare providers to initiate appropriate treatment immediately.
Thyroid hormones are essential for normal brain development, growth, and metabolism. Infants with congenital hypothyroidism often appear normal at birth, making blood testing the primary method for early detection. Without prompt treatment with thyroid hormone replacement therapy, affected children may experience irreversible intellectual disability, growth delays, and other serious health problems.
Low FT4 levels in newborns indicate insufficient thyroid hormone production, confirming the diagnosis of congenital hypothyroidism. The severity of the deficiency helps guide treatment decisions, typically involving lifelong thyroid hormone replacement therapy. With early detection and proper treatment, children with congenital hypothyroidism can develop normally and lead healthy lives.
The information here is for educational purposes only and is not a substitute for professional medical advice. Always consult with a healthcare provider for diagnosis and treatment. Newborn screening programs typically test for congenital hypothyroidism within the first few days of life as part of routine care.